Ardelyx (ARDX) on Thursday said 2025 total product revenue was approximately $378 million, representing 18% year-over-year growth. IBSRELA finished 2025 with full year revenue totaling approximately ...

Robins guided Q1 fiscal 2027 product revenue between $1.262 billion and $1.267 billion, representing 27% year-over-year growth. For full year fiscal 2027, product revenue is expected at approximately ...

Robins guided Q4 product revenue between $1.195 billion and $1.2 billion, representing 27% year-over-year growth, with a non-GAAP operating margin of 7%. Full FY26 product revenue guidance was raised ...

Snowflake raised its fiscal 2026 forecast for product revenue on Wednesday, betting on strong demand for its data analytics services as enterprises prioritize artificial intelligence spending. The ...

Data cloud analytics firm Snowflake on Wednesday raised its forecast for full-year product revenue, as it attracts more clients to its cloud platform owing to advancements in artificial intelligence.

CEO Gary Gillheeney reported that Q3 sales exceeded the high end of guidance, driven by Advanced Wound Care product sales increasing 31% year-over-year and Surgical & Sports Medicine product sales ...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million ...

Cisco Systems Inc (NASDAQ: CSCO) is poised to report its Q3 FY’24 results on May 14, reporting on a quarter that is likely to see the company’s sales contract, as customers focus on deploying hardware ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for ...

Arcutis Biotherapeutics is a biopharmaceutical firm dedicated to creating and commercializing treatments for chronic skin conditions. Its primary product family, ZORYVE, features a range of topical ...

Adjusted net loss attributable to common stockholders is a non-GAAP financial measure which excludes certain items that are included in net loss attributable to common stockholders, the most directly ...